Clinical Research Details

Descriptive Information
A randomized , double blind, multicenter, phase III study of Everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin

Ali Shamseddine
as04@aub.edu.lb

CRAD001T2302
Ongoing

Clinical Research - Clinical Trials (phase 0, 1,2 3 & 4)  

Phase 3  

No
Sponsors
  • Novartis
Conditions and Keywords
Advanced Neuroendocrine tumors of GI or lung origin
Neurodendocrine tumors, Everolimus, GI, Lung
Study Design
Treatment
Safety and/or Efficacy Study
Prospective
Double Blind
Parallel-Group
Randomized
Eligibility and IRB
Both
Min: 18
Max:
Yes
No







Adult patients with histologically confirmed advanced low and intermediate grade nonfunctional NET of GI or lung origin with measurable disease at baseline whose disease progressed within the past six months


Patients with a history of carcinoid syndrome and/or active symptoms of carcinoid at the time of screening are excluded. Poorly differentiated/high grade tumors are excluded.